Renal Testing on the Randox Evidence Series
The Evidence Series of Immunoassay analysers consists of four revolutionary Biochip Array Technology platforms including the Evidence, Evolution, MulitSTAT and Investigator. These analysers can be used in multiple applications including; Clinical Diagnostics, Drug Development, Forensic Toxicology, Food Diagnostics, Academic Research and Veterinary Testing.
Powered by Biochip Array Technology (BAT), the Evidence series is a precise multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
It provides a unique platform for assessment of biological samples in a rapid, accurate and easy to use format.
Based on ELISA principles, the biochip is a solid-state device with discrete test sites onto which antibodies specific to different targets are immobilised and stabilised. Competitive chemiluminescent immunoassays are then employed, offering a highly sensitive screen.
Biochip Array Technology uniquely offers immunoassay diagnostic testing for simultaneous multi-analyte biomarker detection. After addition of a single patient sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.
Each biochip has up to 49 Discrete Test Regions (DTR’s) each detecting a different biomarker. This means that up to 44 tests can be carried out simultaneously. The additional DTR’s are reserved for internal quality control and visual reference, a unique Biochip Array Technology feature.
Our Acute Kidney Injury (AKI) panel can help in the application of patient safety monitoring in the detection of drug toxicity during the clinical trial phases. The detection of drug toxicity in the early stages of a clinical trial is critical to ensure not only patient safety but also saves valuable time and resources in drug development. This is also important in saving valuable research funding with phase I, II & III costing upwards of $30-40 Million1.
Acute Kidney Injury
- Osteopontin – OPN
- Serum creatinine – Creatinine
- Serum cystatin-C – Cystatin-C
- Kidney injury Molecule-I – KIM-I
- Urinary neutrophil gelatinase associated lipocalin – NGAL
Randox’s AKI panel is available as a single sample test on our Biochip Array Technology on our Evidence Investigator Immunoassay Analyser. With a throughput of up to 2376 test per hour, the Evidence Investigator is the perfect platform to detect Acute Kidney Injury, a strong indicator of early stage drug toxicity.
The importance of Renal testing has become ever more prevalent due to the increase of several factors that can lead to chronic kidney disease (CKD) with more evidence demonstrating that AKI can initiate the development or accelerate the progression of CKD2. CKD affects 1 in 10 people worldwide and is incurable, causing patients to need lifelong care3. According to the National Kidney Foundation, the two main causes of CKD are Diabetes and high blood pressure.4. The World Health Organisation estimated that 8.5% of adults aged 18 years and older had diabetes in 2014 and of the 422 million people in the world with type 1 and 2 diabetes, 20-30% will develop diabetic nephropathy, also known as diabetic kidney disease – the leading cause of renal failure in the world5. With this in mind it is vitally important to get tested right away especially if you suffer from diabetes, hypertension or have a family history of kidney failure. Our CKD 7-plex and 4-plex arrays developed in collaboration with National University of Galway demonstrate that a multi-marker approach holds promise for early CKD detection, discrimination of progressive CKD stages and prediction of renal decline.
Chronic Kidney Disease I:
- Fatty Acid Binding Protein I – FABPI
- Soluble Tumour Necrosis Factor Receptor I – sTNFR I
- Soluble Tumour Necrosis Factor Receptor II – sTNFR II
- Macrophage Inflammatory Protein Iα – MIP-Iα
- Interleukin-8 – IL-8
- Epidermal Growth Factor – EGF
Chronic Kidney Disease II:
- Complement C3a Des Arginine – C3a des Arg
- C-Reactive Protein – CRP
- Neutrophil Gelatinase Associated Lipocalin – NGAL
- Cystatin C
- (2018). How much do clinical trials for drugs cost?. [online] Available at: https://www.quora.com/How-much-do-clinical-trials-for-drugs-cost [Accessed 10 Jul. 2018].
- Hartung, T. (2018). Food for Thought Look Back in Anger – What Clinical Studies Tell Us About Preclinical Work. [online] PubMed Central (PMC). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790571/ [Accessed 10 Jul. 2018].
- com. (2018). Chronic Kidney Disease: The Silent Killer – Path Medical. [online] Available at: https://pathmedical.com/ckd-the-silent-killer/ [Accessed 10 Jul. 2018].
- National Kidney Foundation. (2018). About Chronic Kidney Disease. [Online] Avaiable at: https://www.kidney.org/atoz/content/about-chronic-kidney-disease [Accessed 10 Jul. 2018]
- World Health Organisation. (2018) Diabetes. [Online] Available at: http://www.who.int/en/news-room/fact-sheets/detail/diabetes [Accessed 10 Jul. 2018]
World-leading medical diagnostics manufacturer Randox Laboratories is this week showcasing advancements in biotechnology at the world’s largest diagnostics conference, being held in Chicago, Illinois.
The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, known as the leading event for laboratory medicine worldwide, offers Randox the opportunity to showcase their capabilities to more than 20,000 healthcare professionals and decision makers from around the globe.
“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world,” said Randox Managing Director, Dr Peter FitzGerald.
“At AACC we will be hosting demonstrations of a wide range of our intuitive multiplex analysers, including the revolutionary Randox Evidence Evolution, the world’s first fully automated random-access testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.”
The unique and unrivalled capabilities of the Randox Evidence Evolution are made possible thanks to Randox’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously – ensuring an accurate and reliable diagnosis as fast as possible.
Launching at this year’s AACC event are a number of exciting new tests on the Randox Biochip, the result of a £280 million investment in research and development. Including but not exclusive to a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in the participants of pharmaceutical drug trials, these new tests all share the common goal of much earlier and effective diagnosis, to greatly improve healthcare outcomes and reduce the burden on healthcare services.
Dr. FitzGerald continued;
“We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US.
“Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market.
“We look forward to showcasing our latest innovations at this year’s AACC conference, and how they can be utilised to save, improve and extend lives through the earliest possible diagnosis. Randox technology can truly revolutionise the future of healthcare.”
AACC runs from the 29th July – 2nd August at McCormick Place in Chicago, Illinois. Randox can be found at booth #3624.
For further information visit aacc.randox.com
Lactic acid is an organic compound which produces the conjugate base lactate through a dissociation reaction. Due to it being a chiral compound, two optical isomers of lactate exist; D-Lactate and L-Lactate. The lactate dehydrogenase (LDH) enzyme can produce and metabolise both isomer forms to pyruvate, however due to the isomer-specific nature of LDH different forms of the enzyme are required. D-Lactate requires a D-LDH form whereas L-Lactate requires L-LDH. As a result of this requirement, combined with the fact that mammalian cells only contain L-LDH, the lactate produced in humans is almost exclusively L-Lactate.
One of the roles of L-Lactate is its involvement in the Cori Cycle, a metabolic pathway involved in the production of glucose. The cycle involves the rotatory transportation of lactate and glucose from the liver and the muscle. Lactate is produced in the muscle through glycolysis which is then transported to the liver through the blood stream. In the liver, the lactate is oxidised to pyruvate and then converted to glucose by gluconeogenesis, which is then transported back to the muscle for the process to start again. 1500 mmol of lactate is produced daily by the body and is cleared at a constant rate via the liver.
Problems can arise if the liver fails to regulate the lactate produced. Hyperlactamia is the name given to elevated levels of lactate in the body, as a result of the rate of production exceeding the rate of disposal. This is due to a lack of oxygen that reduces blood flow to the tissues. If levels continue to rise a patient is at risk of lactic acidosis.
The liver is an important tissue in the regulation of lactate, it is therefore no surprise that liver damage can prevent this process resulting in a further diagnosis of lactic acidosis. A healthy liver is a vital part of lactate regulation as it acts as the main consumer of lactate and contributes to 30-40% of lactate metabolism. Potential victims are patients who suffer with cirrhosis, a complication of liver disease, which is commonly caused by alcohol abuse and viral Hepatitis B and C.
Patients with liver cirrhosis have a higher risk of increased lactate levels. Increased levels of the lactate ions disturbs the acid-base equilibrium, causing a tilt towards lactic acidosis. The mortality rate of patients who develop lactic acidosis is high, prompt recognition and treatment of the underlying cause remain the only realistic hope for improving survival.
The Randox L-Lactate reagent allows for a prompt and accurate diagnosis of lactic acidosis.
Randox L-Lactate Reagent
The Randox L-Lactate key benefits include:
- Excellent working reagent stability of two weeks when stored at + 15 – +25°C
- Exceptional correlation of r = 0.99 when compared against other commercially available methods
- A wide measuring range of 0.100 – 19.7 mmol/l and so is capable of detecting abnormal levels in a sample
- Colorimetric method
- Lyophilised reagents for enhanced stability
Cannabis continues to be the most reported drug abused in Sri Lanka, however cannabis related offences have decreased from 66.2% to 61.9% in April – May 2018. Heroin is the second highest drug abused at 28.8% of those arrested in April and 35.9% of arrestees in May engaging in heroin related offences. Hashish, babul, madana modaka, opium, methamphetamine and tablets are other prevalent drugs abused in Sri Lankan drug related offences that have been noted. Although cannabis related crime has decreased, drug prevalence and drug related offences are increasing in the country.
Sri Lanka has been taking measures to tackle the abuse of opium, cannabis and certain psychotropic substances since its independence in 1948. Opium is not cultivated in Sri Lanka, however over the past decade Sri Lanka has been used as a trans-shipment point for heroin from South West Asia and India to other destinations outside of the subcontinent. Heroin seized prior to reaching Sri Lanka is roughly two – three times the quantity of heroin seized in Sri Lanka itself.
Randox Toxicology are the leading manufacturer of the patented Biochip Array Technology (BAT). BAT is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. After the addition of a sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.
Additionally, our range of immunoanalysers include the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT which individually utilise our Biochip Array Technology for the screening of drugs of abuse. Our extensive toxicology test menu covers a broad range of classical, prescription, synthetic drugs and new psychoactive substances. With multiple matrices available, Randox Toxicology are a global leader in the Toxicology market.
Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our DoA II panel can detect opium and generic opioids. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends.
The main depression charity for Northern Ireland, AWARE has an established network of 24 support groups in rural and urban areas across the country, and also delivers mental health and well-being programmes into communities, schools, colleges, universities and workplaces. Mind Your Mood is an initiative designed and managed by students at Ulster University to help break down the stigma of mental health and encourage students to access support.
Randox will be fundraising for the charities through a range of events and initiatives throughout the year, including individual staff fundraising activities, the company’s annual staff fun day, Randox Fest, and its popular Christmas Raffle.
Randox Founder and Managing Director, Dr Peter FitzGerald, commented;
“Mindful of the significant impact of mental health issues on society, we are today announcing AWARE and Mind Your Mood as our charity partners for the year. Every one of us has been touched either directly or indirectly by these issues and it’s something we at Randox wish to help to address. We have for example invested significantly in research that will determine how problems with the digestive system can affect your mood, sleep and stress levels. We hope that our partnerships not only help those affected by mental ill-health across Northern Ireland, but also empower our Randox staff to take care of their own mental well-being.”
In addition to supporting AWARE and Mind Your Mood with fundraising events throughout the year, Randox has also committed to delivering mental health awareness sessions and mindfulness activities to its staff.
Inclusive of the introduction of the Mood Matters Workplace Programme, and the provision of dedicated Mental Health Mentors, Randox hopes to encourage staff to effectively manage their feelings when they’re stressed, worried or depressed, learn simple practical skills to help cope with their own challenges, and support their colleagues with theirs.
Clare Galbraith, Corporate Fundraising Officer for AWARE, commented;
“We’re delighted to have Randox on board as one of our official corporate fundraising partners this year. As a key employer in Northern Ireland with tremendous influence, the company has real potential to transform how we look at mental health and wellbeing, particularly in the workplace setting. We look forward to seeing the creative fundraising ideas they have planned for the year ahead and thank them for all their support thus far.”
Amanda Castray, Director of Campus Life, Ulster University said,
“Ulster University and Randox enjoy a longstanding partnership built around research, knowledge sharing, collaboration and student opportunity which reflects the leadership of both organisations in diagnostics and health research globally. We are very encouraged that one of our valued industry partners is now supporting us with our student-led mental health programme, Mind Your Mood. We look forward to working with the team at Randox as we promote positive mental health and wellbeing across our campuses and tackle the social stigmas associated with seeking support.”
As part of Randox’s focus this year on mental health and wellbeing, the global healthcare company will also be offering Ulster University students a discount on its revolutionary health checks for the duration of the partnership.
These health programmes are designed to find indicators of physical or mental ill-being at the earliest possible stage, to allow preventive action or treatment to be taken.
For further information about AWARE, and the opportunity to donate, please visit www.randox.com/aware/
For further information about Mind Your Mood, and the opportunity to donate, please visit www.randox.com/mind-your-mood/
For other enquiries, please contact Randox PR on 028 9442 2413 or email firstname.lastname@example.org
Did you know that copper is an essential trace mineral present in all tissues? It works with iron to help the body form red blood cells. It also helps keep the blood vessels, nerves, immune system and bones healthy while also aiding in iron absorption. In rare situations, copper deficiency can occur and lead to anaemia and osteoporosis.
Symptoms of copper deficiency include:
- Fatigue & weakness as cells use copper to generate ATP, the body’s main source of energy. This means that copper deficiency could affect your energy levels.
- Frequent sickness as copper plays an important role in maintaining a healthy immune system.
- Weak and brittle bones as copper is involved in the processes that create cross-links inside your bones. These cross-links ensure bones are healthy and strong.
- Problems with memory and learning as copper plays an important role in brain function and development.
Sensitivity to cold as copper, along with minerals like zinc, help maintain optimal thyroid gland function. Low thyroid levels can make you feel colder more easily.
There are many foods that are high in copper. These include leafy greens, including turnip, greens, spinach, kale and mustard greens. Asparagus and summer squash are two other excellent sources of copper while legumes, whole grains, nuts and seeds are also good sources of the substance.
Randox Reagents, RX and QC are helping to diagnose copper deficiency at the earliest possible stage. The Randox copper assay is used to measure the levels of copper in the blood in order to determine copper toxicity. Combining this with the Randox zinc assay can aid in identifying the cause of liver damage in a patient, leading to correct treatment and recovery.
Find out more about how Randox is helping to diagnose nutritional status and deficiencies here: https://www.randox.com/nutritional-status/
The potential presence of drug residue contaminants in food products destined for human consumption is an increasingly popular topic of conversation in the industry but what are the main challenges facing the industry to tackle this potential issue?
Drug residue contaminants in food products is a discussion that involves the global community but each individual country or trade bloc has their own protocols and regulations relating to the control and monitoring of residues. The different legislations are designed to protect the general public as well as the food industry interests in their individual countries. Any business that wishes to sell their products within other countries or regions must meet their legislative requirements relating to drug residues. These differences in regulations have increased the need for increased dialogue on the issue as well as the implementation of effective monitoring systems.
The industry must deal with the potential of residues from antibiotics and growth promoting hormones entering the food chain. This will involve ensuring correct dosage per animal and also adhering to withdrawal periods set for their region. The second issue the industry faces is the stigma received from the misuse of these antibiotics and growth promoting hormones.
While there is a potential for misuse it should always be noted that a producer’s main concern should always be animal health, which leads to a quality end product. The use of antibiotics is to ensure the health of the animal and to reduce the potential knock on effect of untreated diseases which could create a downturn on yield. Growth promoting hormones are used to increase this yield also but should never be done so at the expense of a safe end product.
Residues from particular drugs in food produce can have serious implications for human health. As such many countries have set Maximum Residue Limits (MRLs) or tolerances for these residues in food. The Maximum Residue Limit is the maximum concentration of a residue that can be present in a product from an animal or animal by product intended for the food supply. These MRLs mean that it is required by law in the enforcing countries that any product in the food chain cannot contain residue levels that are harmful to human health above these limits.
There has been controversy over measures to tackle drug residues in foods as there are no internationally accepted standards for many drugs. Ractopamine in particular has caused trade disputes as it is permitted in food production in some countries like the US & Canada, but the European Union, China, Taiwan and over 100 other countries have banned its use.
The real challenge the food industry faces is ensuring their testing methods are effective and reliable to ensure the safety of a variety of end products. To name a few of these diverse products we can look at the dairy, meat, seafood, feed and honey markets.
The dairy industry is under constant scrutiny and pressure to constantly produce high volumes of milk whilst maintaining a superior standard of quality in their dairy products. As part of the production process various contaminants are administered to cattle in an effort to systematically treat various infectious diseases and maintain a healthy herd. A direct consequence of this is the requirement of routine monitoring and testing within farms and dairy processors to ensure that the levels of contaminants in milk are within legal regulations not exceeding Maximum Residue Limits and that unauthorised substances are not found at any level in milk.
Testing can be conducted at several points during the production process. Firstly, farm level testing can be carried out to screen milk from cows that have been separated from the herd and undergone antibiotic treatment. Secondly, the dairy processor is required to conduct testing both onsite taking samples from tankers and retrospective testing as a method of internal surveillance to ensure the milk supplied from several farms is within global regulatory limits. Thirdly, retailers can test the processed milk end product to guarantee the milk is antibiotic free before it’s added to supermarket shelves for consumers.
Global meat production and consumption have increased rapidly in recent decades. Worldwide meat production has tripled over the last four decades and increased 20 percent in just the last 10 years. Meanwhile, industrial countries are consuming growing amounts of meat, nearly double the quantity in developing countries. Mass quantities of antibiotics are used on livestock to reduce the impact of disease, contributing to antibiotic resistance in animals and humans alike. Worldwide, 80 percent of all antibiotics sold in 2009 were used on livestock and poultry, compared to only 20 percent used for human illnesses.
Growth promoters, which are tested for under the NRCP, are hormonal and antibiotic substances that may be used in food producing animals for growth promotion in livestock animals thus increasing the production of muscle meat and the reduction of fat. The type of growth promoter used is dependent on the animal species and mode of rearing with steroid growth promoters used for beef cattle and antibiotic growth promoters, which are usually added to feedstuffs, such as the coccidiostats used in the poultry industry and chlortetracycline used in the porcine industry. The rapid speed of meat production calls for the need to test for drug residues frequently to prevent them from ending up in the food chain.
The global aquaculture industry has grown steadily over the past five decades, increasing at an average rate of 3.2%. However, this growth has come at a cost, with the industry facing many new challenges. Farmed seafood is often treated with medicated feeds which contain antibiotics such as leucomalachite green and nitrofurans for example to prevent from disease spreading, they are also exposed to other harmful residues used to treat algae etc. within the ‘pens’ where they are kept.
The FAO (2012) reported that 38% of fish produced globally is exported, highlighting the imbalances in regional supply and the changing tastes of the global consumer. This increased level of exporting and importing shows the importance of drug residue screening within the global aquaculture industry. This increased level of exporting and importing shows the importance of drug residue screening within the global aquaculture industry.
The global animal feed processing market is estimated at US$21.61 billion in 2018 and is projected to reach US$ 26.62 Billion by 2023. The market is driven by factors such as the rising awareness of feed nutrition and health, technological advancements in the equipment industry and increase in the demand for feed around the world. Medicated feeds containing veterinary are often used to help prevent disease within livestock and there are MRLs for feed which has created the need for testing as high levels of residues can have an effect on livestock health and also transfer through to meat products for human consumption. With humidity levels rising in recent years there has been an influx in the level of mycotoxins found within feed and cereals. These toxins are fungal and can affect both livestock and human health for example mycotoxicoses which is a disease which can affect the respiratory system. The main cause of mycotoxins within stored grains are when the grain is damp or cracked and kept in insufficient storage conditions. These factors have made it necessary for feed and cereals to be tested for both drug residues and mycotoxins to ensure that they do not end up within the food chain.
The global honey market is growing at a rapid pace and the global consumption of honey is to reach 2.5 million tones by 2022. This growth is driven for consumers demand for natural and healthy alternatives to artificial sweeteners over cane sugar. There is also a growing awareness of the health and healing benefits of honey which is driving the demand for the use of honey for medicinal use, manuka honey sales continue to grow for its antibacterial and anti-inflammatory properties. The rapid rise in demand for honey outweighs the amount that can be produced in a natural form globally due to a decline in the number of bees. This has influenced the quality of honey being produced as some producers take to diluting natural honey with high-fructose corn syrups in order to supply the demand. There is a requirement for keepers to treat bee colonies with antibiotics to prevent CCD and other diseases such as varroa mites and there is a chance that these harmful drug residues can be transferred through to the end product ‘natural’ honey. The use of antibiotic drugs in apiculture is globally restricted and there are no MRLs set for antibiotics in honey as it a natural product and needs to be antibiotic free, this has cause the need for testing both for drug residues and the overall quality of the honey being produced.
Due to the requirement to use a variety of drug treatments in the food industry and also the potential economic benefits to be gained from the use of growth promoters, there will continue to be use in animal production. However, as analytical methods of detection become more sensitive, producers are given further options for testing.
The surveillance for the potential presence of these residues of veterinary substances is regulated by the EU Directive 86/469/EEC. This directive outlines the guidelines for sampling and testing within a residue monitoring programme.
The requirement to meet these standard and the MRLs and detection levels outlined in the legislation has created a need for analytical methods to become more sensitive to ensure correct analysis. On some occasions MRL’s have been lowered which require a technology sensitive enough to detect very low concentrations in a sample.
One such screening method that is commonly used is the Enzyme-linked immunosorbent assay (ELISA) methods, which work well for testing and providing accurate results.
Randox Food have developed another method of analysis using the Evidence Investigator which uses similar methodology to ELISA methods. The analyser uses biochip array technology (BAT) to perform simultaneous quantitative detection of multiple analytes from a single sample and can be used across multiple matrix types including the products produced by the industries mentioned. The core technology is the Randox biochip, this contains an array of discrete test regions containing immobilized antibodies specific to the drug residues under test.
These methods are rapid, reliable, and sensitive so are able to detect residues in very small concentrations. The Randox methods are developed in line with EU Directive 86/469/EEC and as such are an effective testing method for multiple areas of the food industry.
For further information please contact the Randox Food Diagnostics team by emailing: email@example.com
The aim of Biomedical Science Day is to raise the public’s awareness of the importance of biomedical science and the vital role it plays in the world. Randox are dedicated to improving healthcare worldwide through placing a major focus on research and development. The Randox scientists work in pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.
A recent blog from Doris-Ann Williams, the Chief Executive at BIVDA, explains how “increased funding is not enough to sustain the NHS” and how “we need to make better use of in vitro diagnostics to ensure a successful future”.
The National Health Service (NHS) is a publicly funded, primarily taxation, national healthcare system in the United Kingdom. It was first set-up on July 5th, 1948 by Aneurin Bevan as he believed that everyone, regardless of wealth, should have access to good healthcare. Whilst the NHS is an extremely important aspect of healthcare in the UK, in vitro diagnostics are the heart and soul of the healthcare system as healthcare professionals not only rely on blood tests to diagnose and treat patients, but also to rule out the different contributing causes to a disease state. In vitro diagnostics also plays a key role in monitoring chronic disease states. In vitro diagnostics can also aid in reducing hospital stays, reduce misdiagnosis and support patients in looking after their own health and to deliver personalised treatment plans.
The Randox scientists have developed several niche assays to improve patient diagnosis, monitor treatment and eliminate misdiagnosis.
Adiponectin is a protein hormone secreted by adipocytes with anti-inflammatory and insulin-sensitising properties. It plays an important role in a number of metabolic processes including glucose regulation and fatty acid oxidation. Adiponectin levels are inversely correlated with abdominal visceral fat which have proven to be a strong predictor of several pathologies, including: metabolic syndrome, type 2 diabetes mellitus (T2DM), cancers and cardiovascular disease (CVD). For more information on the importance of testing Adiponectin levels, check out our Adiponectin Whitepaper.
Cystatin C is an early risk marker for renal impairment. The most commonly run test for renal impairment is Creatinine. Creatinine measurements have proven to be inadequate as certain factors must be taken into consideration, including age, gender, ethnicity etc. The National Institute for Health and Care Excellence (NICE) have updated their guidelines, which now recommends Cystatin C as a more superior test for renal impairment due to its higher specificity for significant disease outcomes than those based on Creatinine. For more information on the importance of testing Cystatin C levels, check out our Cystatin C Whitepaper.
Small-dense LDL Cholesterol (sdLDL-C)
LDL Cholesterol (LDL-C) consists of two parts: the large and buoyant LDL Cholesterol and the small and dense LDL Cholesterol. Whilst all LDL-C transports triglycerides and cholesterol to bodily tissues, their atherogensis varies according to their size. As sdLDL-C is small and dense, they can more readily permeate the arterial wall and are more susceptible to oxidation. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction. It has been noted that sdLDL-C carries less Cholesterol than large LDL, therefore a patient with predominately sdLDL-C particle may require nearly 70% more sdLDL-C particles to carry the same amount of cholesterol as the patient with predominately LDL-C particles. For more information on the importance of testing sdLDL-C levels, check out our sdLDL-C Whitepaper.
These three niche in vitro diagnostics tests developed by Randox scientists can aid in reducing NHS costs due to their higher performance compared to the traditional tests. Randox are constantly striving to improve healthcare worldwide.
For more information on the extensive range of Randox third-party in vitro diagnostic reagents, visit: https://www.randox.com/diagnostic-reagents/ or contact firstname.lastname@example.org.
Biomedical Science Day is taking place this year on the 19th of July. This is an annual celebration with the aim of raising public awareness of the importance of biomedical science and the vital role it plays in the world.
To celebrate biomedical science day the RX series interviewed Aidan Murphy, one of our laboratory analysts at Randox to find out more about what his job in the lab entails day-to-day. Aidan works with the RX series of clinical chemistry analysers and Randox QC on a daily basis.
We asked Aidan a few questions about his life as a scientist. See what he gets up to in Randox on a daily basis …
1. What attracted you to a career in laboratory science?
Science has always interested me in both my academic and personal life, I always aspired to get a science based degree and after achieving this I now hope to improve my laboratory skills to increase my employability.
2. What were your stronger subjects at school?
My strongest subjects in school were biology, chemistry, music and politics. Some of which are more applicable to my current role than others.
3. What does your job in Randox entail?
My job entails a variety of roles ranging from testing Randox diagnostic kits before they’re released to customers as well as maintenance and precision checks of the machines in our lab.
4. What aspects of your job do you enjoy the most?
The independence in my job is great. Knowing what I have to do at the start of each week and the deadlines to do these jobs requires me to organise and prioritise my work accordingly.
5. What are some common preconceived ideas the public have about what laboratory staff do?
From my friends’ ideas of what I do in the lab I have found that a stereotypical image of a lab is one of a dark quiet lab full of strange equipment and even stranger people. However fortunately my lab is a lively one and thankfully with normal people.
6. In your opinion, what are the most important aspects of laboratory work?
Following correct protocols and procedures are imperative in an efficient laboratory. As well as this, good lab practice and good hygiene can have a massive effect on the accuracy of our results.
7. What’s in your lab coat pocket?
My lab coat pockets are quite boring. I have a pair of safety goggles, some post-its and some pens and markers.
8. In what ways does your work make a difference to people’s lives?
Randox is dedicated to improving the quality of diagnostics globally, so knowing that the kits that I have tested are then sent to customers to be used in patient diagnosis gives me a level of job satisfaction that I haven’t got from previous jobs.
Aidan is a fundamental member of the Randox team and plays an essential role in the diagnosis and prevention of disease through his work. Without our valuable laboratory team working extremely hard behind the scenes the lifesaving work we do here at Randox would not be possible.
To find out more about Randox products contact us at theRXseries@randox.com.
Check out our social media sites for more on Biomedical Science Day.
“Family Law defines the legal attributes of the status, for example, the mutual rights and obligations of the married couple and provides remedies for regulating the relationship of the parties. Family Law determines the status of a child and provides mechanisms for regulating the exercise of parental responsibility.” – James Munby
James Munby spoke on the social justice for children and families and outlined the aims of the family justice system. He concluded with the ultimate aim stressing that the system must be about ‘securing social justice for children and their families.’
In specific circumstances in family law cases testing for drugs and alcohol may be required by various professional bodies involved in child custody cases, care proceedings or child protection cases. In cases regarding divorce and children, a dispute may arise during the process of discussions involving the custody of children. In these cases drug and alcohol testing may be sought if there has been a substance abuse claim against a parent fighting for custody or visitation.
Family law drug and alcohol testing is important to ensure child protection from the detrimental effects of parental substance misuse and to ensure they have a quality of life they deserve. In addition it is also important to enable parents the opportunity to get the help and support they need and begin rehabilitation treatment. Doing the right thing by the child is the main priority, and where possible parent and child relationships are sought to be maintained.
Randox Testing Services – Medical Review
The comprehensive medical review service from Randox Testing Services offers independent and expert examination of positive results under medical confidentiality. As a cause for concern, positive results are recognised as a serious trade issue in all areas of drug and alcohol testing be it employee testing, testing carried out for family law issues or forensic toxicology.
A medical review report provides a detailed analysis of results to determine if there is a legitimate medical reason for positive results. Performed by a Medical Review Officer (MRO) the assessment involves a donor’s medical background to determine if, for example, a donor is taking or has taken in the recent past any prescriptive medication that may have affected results.
Our medical review service ensures confidence in results by eradicating any wrongful conclusions being made while helping to protect the rights of the person being tested and the person requiring the testing.
Family Law solicitors involved in care proceedings must take seriously the consequences of a parent or guardian testing positively for drugs or alcohol. The wrongful conclusion of a positive test result could lead to child parent separation for those involved in a custody battle or child protection case and cause unnecessary stress and anguish. A medical review protects the rights of all involved and ensures trust in the legal sector is maintained by determining legitimate reasons for a positive result while eradicating false conclusions from being made.
Randox Testing Services – Expert Witness Report
An expert witness report is a document providing a detailed outline of the drug and alcohol testing procedure followed and an interpretation of the results found. It is used as objective evidence in court and provides a detailed explanation of whether or not substances tested for were detected as well as information regarding chain of custody compliance.
Family law solicitors or social services may require an expert witness report for use in care proceedings relating to a dispute over the custody of children, or an issue concerning child protection. An expert witness report ensures non-biased and factual evidence for use in family court and guarantees confidence in results by ensuring sample integrity has been maintained throughout the testing process. In addition strict chain of custody procedures guarantees donor confidentiality which is vital in family court care proceedings.
Contact us today at email@example.com or call 0 161 741 2760 to speak to one of our experts.